- Home
- ETON vs BCYC Comparison
ETON vs BCYC Comparison
Compare ETON & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | BCYC |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 438.4M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ETON | BCYC |
|---|---|---|
| Price | $16.57 | $7.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $29.67 | $18.73 |
| AVG Volume (30 Days) | 326.6K | ★ 329.4K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,316,000.00 | $28,339,000.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $6.03 |
| 52 Week High | $23.00 | $21.50 |
Technical Indicators
Market Signals| Indicator | ETON | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 50.66 |
| Support Level | $15.28 | $6.76 |
| Resistance Level | $17.00 | $7.83 |
| Average True Range (ATR) | 0.82 | 0.42 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 38.55 | 58.06 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.